10x Genomics Price to Free Cash Flow Ratio 2018-2024 | TXG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

10x Genomics price to free cash flow ratio from 2018 to 2024. Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

10x Genomics price to free cash flow ratio from 2018 to 2024. Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Tempus AI (TEM)	$11.4B
Inspire Medical Systems (INSP)	$5.9B
Hims & Hers Health (HIMS)	$5B
Axonics (AXNX)	$3.6B
IRhythm Technologies (IRTC)	$2.7B
Enovis (ENOV)	$2.6B
Privia Health (PRVA)	$2.5B
Omnicell (OMCL)	$2.3B
Azenta (AZTA)	$2.2B
Clover Health Investments (CLOV)	$1.7B
Schrodinger (SDGR)	$1.4B
Phreesia (PHR)	$1.2B
Standard BioTools (LAB)	$800M
Fulgent Genetics (FLGT)	$589M
Butterfly Network (BFLY)	$558M
Talkspace (TALK)	$555M
Definitive Healthcare (DH)	$500M
Health Catalyst (HCAT)	$498M
Pulmonx (LUNG)	$294M
SOPHiA GENETICS SA (SOPH)	$230M
TruBridge (TBRG)	$203M
American Well (AMWL)	$135M
P3 Health Partners (PIII)	$134M
EUDA Health Holdings (EUDA)	$108M
HeartBeam (BEAT)	$68M
Future Health ESG (FHLT)	$65M
111 (YI)	$59M
Zepp Health (ZEPP)	$49M
SHL Telemedicine (SHLT)	$45M
CareCloud (CCLD)	$44M